A Phase 2/3 interventional study of Physiologic Estrogen/progesterone and Placebo in Anorexia Nervosa, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to female participants aged 12 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-02.
Sponsored by Massachusetts General Hospital · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Anorexia Nervosa by Massachusetts General Hospital — 2 open to participants now, 2 under way, none of them phase 3. Anorexia Nervosa · Massachusetts General Hospital.
Among the 16 studies in Anorexia Nervosa by Massachusetts General Hospital, this one is the 4th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2003, is one of 2 in phase 2/3, and was the 1st registered.
471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.
Browse Anorexia Nervosa studies →2 of the 16 studies in Anorexia Nervosa by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18–65 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.
This study: 12 Years to 18 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 4
First in 2003; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 46 across 314 interventional studies indexed under Anorexia Nervosa.
Median enrollment 40 across the 15 interventional studies, 61 across the 1 observational. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Anorexia Nervosa by Massachusetts General Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to determine the effects of anorexia nervosa on bone mass and hormone levels in adolescents. Whether administration of estrogen, a normal hormone present during puberty, can help maintain bone development in girls with anorexia nervosa will be determined.
Adolescence is a critical time for bone mineral accretion as between 60-90% of peak bone mass is established during this period, and peak bone mass is a major determinant of bone density and osteoporosis risk during adulthood. Anorexia nervosa (AN) is the third most common chronic illness among adolescent girls, with a prevalence of 0.2-1.0%. Therefore, AN occurs at a time during which patients are the most vulnerable to disruption of bone mineral accretion. Osteopenia is a major co-morbid complication of AN in 50-75% of female adolescents and adult women with this eating disorder. Women with the onset of the disorder during adolescence have more severe osteopenia than women with onset during adulthood. Little is known about the pathogenesis of osteopenia in this adolescent population and there are no established therapies. Improved understanding of bone mineral metabolism and factors which predict recovery of bone mineral accretion are critical in the development of therapeutic strategies to preserve and maximize bone mass in girls with the onset of AN during adolescence. Estrogen is known to be a critical factor in the development of peak bone mass. Although AN is associated with profound estrogen deficiency, there are no controlled studies investigating the effects of estrogen administration in this population.
This research proposal will address critical unanswered questions regarding bone abnormalities in adolescents with anorexia nervosa. Defining changes in bone formation with weight recuperation and hormonal variables would provide insight into the factors essential for bone mineral accretion during adolescence, as well as those that predict recovery. Determination of dose-dependent estrogen effects in this population will be key in targeting interventions during the time of active disease, with the long-term goal of preserving peak bone mass accretion in this vulnerable group of patients. Data obtained from women with post-menopausal osteoporosis or from women with AN cannot be extrapolated to adolescent patients who are in an active period of bone growth and mineralization as well as remodeling. Given the increasing prevalence of AN and its profound consequences on bone health, these studies will provide much needed data to enable treatment strategies for this severe co-morbid disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Mature girls with anorexia nervosa (AN) (bone age 15 or greater): Transdermal estradiol (100 mcg) with cyclic progesterone (days 1-10 of each month). Immature girls with AN (bone age less than 15 years): Ethinyl estradiol (3.75 mcg daily for the first 6 months, 7.5 mcg daily for the next 6 months, and 11.25 mcg daily for the final 6 months of the study
Drug: Physiologic Estrogen/progesterone
Placebo patches or pills
Other: Placebo
Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month
Also known as: Bone age >=15: Vivelle Dot patch with cyclic Provera
Placebo patches twice weekly; Placebo pills daily for the first 10 days of every month
Percent Change in Spine Bone Density Over the Study Duration (18 Months)
Bone density at the spine (lumbar 1-4 vertebrae) was measured using dual energy x-ray absorptiometry (DXA) at baseline, 6 months, 12 months and 18 months. The primary outcome was the percent change in bone density at the spine from baseline to 18 months. Areal bone density is measured as g/cm2. The unit of measure for the percent change in bone density is 'percent' Percent change in bone density= \[\[Bone density at 18 months- Bone density at baseline)\*100/Bone density at baseline\]%
Time frame: Baseline and 18 months
Change in Spine Bone Mineral Density Z-scores Over the Study Duration (18 Months)
Bone density at the spine (lumbar 1-4 vertebrae) was measured using dual energy x-ray absorptiometry (DXA) at baseline, 6 months, 12 months and 18 months. The other primary outcome was the change in spine bone density Z-score from baseline to 18 months. The bone density Z-score is a standard deviation score that compares one's bone density to the mean for age and gender, and the Z-score, therefore, does not have any units. It is simply referred to as a Z-score. Change in bone density Z-score= \[Bone density Z-score at 18 months- Bone density Z-score at baseline\]
Time frame: Baseline and 18 months
Change in N-terminal Propeptide of Type 1 Procollagen (P1NP) Over the Study Duration (18 Months)
P1NP is a surrogate marker of bone formation that is measured in serum. P1NP levels were measured at baseline, 6, 12 and 18 months. A secondary outcome was the change in P1NP levels from baseline to 18 months: \[P1NP at 18 months - P1NP at baseline). The unit is ng/ml
Time frame: Baseline and 18 months
Period of recruitment: 2003-2009. Location: Massachusetts General Hospital (Boston) and Hospital for Sick Children (Toronto). We screened 150 girls with anorexia nervosa (AN) (110 at MGH and 40 at SickKids) and 88 normal-weight controls 12-18 years. Following the screen, 110 AN and 40 controls were enrolled for the prospective study.
| Milestone | Physiologic Estrogen Replacement | Placebo |
|---|---|---|
| Started | 55 | 55 |
| Completed | 31 | 30 |
| Not completed | 24 | 25 |
| Withdrew: Physician decision | 3 | 3 |
| Withdrew: Withdrawal by subject | 10 | 10 |
| Withdrew: Lost to follow-up | 11 | 12 |
Bone density at the spine (lumbar 1-4 vertebrae) was measured using dual energy x-ray absorptiometry (DXA) at baseline, 6 months, 12 months and 18 months. The primary outcome was the percent change in bone density at the spine from baseline to 18 months. Areal bone density is measured as g/cm2. The unit of measure for the percent change in bone density is 'percent' Percent change in bone density= \[\[Bone density at 18 months- Bone density at baseline)\*100/Bone density at baseline\]%
| Percent change | Physiologic Estrogen Replacement | Placebo |
|---|---|---|
| Percent Change in Spine Bone Density Over the Study Duration (18 Months) | 2.6 ± 1.0 | 0.3 ± 0.1 |
P1NP is a surrogate marker of bone formation that is measured in serum. P1NP levels were measured at baseline, 6, 12 and 18 months. A secondary outcome was the change in P1NP levels from baseline to 18 months: \[P1NP at 18 months - P1NP at baseline). The unit is ng/ml
| ng/ml | Physiologic Estrogen Replacement | Placebo |
|---|---|---|
| Change in N-terminal Propeptide of Type 1 Procollagen (P1NP) Over the Study Duration (18 Months) | -2.9 ± 22.5 | -10.9 ± 27.0 |
Bone density at the spine (lumbar 1-4 vertebrae) was measured using dual energy x-ray absorptiometry (DXA) at baseline, 6 months, 12 months and 18 months. The other primary outcome was the change in spine bone density Z-score from baseline to 18 months. The bone density Z-score is a standard deviation score that compares one's bone density to the mean for age and gender, and the Z-score, therefore, does not have any units. It is simply referred to as a Z-score. Change in bone density Z-score= \[Bone density Z-score at 18 months- Bone density Z-score at baseline\]
| Z -scores | Physiologic Estrogen Replacement | Placebo |
|---|---|---|
| Change in Spine Bone Mineral Density Z-scores Over the Study Duration (18 Months) | -0.026 ± 0.078 | -0.236 ± 0.091 |
Collected over 18 months for each subject(AN E+ versus AN E-). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Physiologic Estrogen Replacement | — | 12/55 (21.8%) | 18/55 (32.7%) |
| Placebo | — | 16/55 (29.1%) | 20/55 (36.4%) |
| Event | Physiologic Estrogen Replacement | Placebo |
|---|---|---|
| Hospitalizations for low weight and/or bradycardiaGeneral disorders | 12/55 | 16/55 |
| Increased vaginal bleedingReproductive system and breast disorders | 1/55 | 0/55 |
| Erythema at patch application siteSkin and subcutaneous tissue disorders | 0/55 | 1/55 |
| PregnancyReproductive system and breast disorders | 0/55 | 1/55 |
| Suicidal ideationPsychiatric disorders | 1/55 | 1/55 |
| Event | Physiologic Estrogen Replacement | Placebo |
|---|---|---|
| Erythema at patch application siteSkin and subcutaneous tissue disorders | 17/55 | 19/55 |
| BloatingGastrointestinal disorders | 18/55 | 16/55 |
| Nausea/vomitingGastrointestinal disorders | 14/55 | 8/55 |
| HeadachesNervous system disorders | 10/55 | 14/55 |
| Breast tendernessReproductive system and breast disorders | 14/55 | 9/55 |
| Increased vaginal dischargeReproductive system and breast disorders | 13/55 | 9/55 |
| Increased uterine bleedingReproductive system and breast disorders | 13/55 | 9/55 |
| DizzinessVascular disorders | 6/55 | 10/55 |
| Perceived loss of scalp hairSkin and subcutaneous tissue disorders | 8/55 | 5/55 |
| Irritation from contact lensesEye disorders | 2/55 | 6/55 |
| Age, Categorical(Participants) | Physiologic Estrogen Replacement | Placebo | Total |
|---|---|---|---|
| <=18 years | 55 | 55 | 110 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Physiologic Estrogen Replacement | Placebo | Total |
|---|---|---|---|
| Mean | 16.6 ± 1.6 | 16.3 ± 1.6 | 16.5 ± 0.2 |
| Sex: Female, Male(Participants) | Physiologic Estrogen Replacement | Placebo | Total |
|---|---|---|---|
| Female | 55 | 55 | 110 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | Physiologic Estrogen Replacement | Placebo | Total |
|---|---|---|---|
| United States | 55 | 55 | 110 |
The record gives a start of Jul 2003, a primary completion of Feb 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →